Patient empowerment: rofecoxib revisited.
Tannenbaum
Hyman
H
D000368:Aged; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D030881:Disclosure; D006801:Humans; D007783:Lactones / Q000009:adverse effects / Q000627:therapeutic use*; D010003:Osteoarthritis / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D010344:Patient Advocacy; D010358:Patient Participation; D017060:Patient Satisfaction; D010817:Physician-Patient Relations; D013450:Sulfones / Q000009:adverse effects / Q000627:therapeutic use*
D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib